Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneDx Holdings's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 64.
GeneDx Holdings's Days Inventory for the
three
months ended in Jun. 2026 was 37.89.
GeneDx Holdings's Days Payable for the
three
months ended in Jun. 2026 was 20.56.
Therefore, GeneDx Holdings's Cash Conversion Cycle (CCC) for the
three
months ended in Jun. 2026 was 81.33.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
GeneDx Holdings Cash Conversion Cycle Related Terms
GeneDx Holdings Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for GeneDx Holdings's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WGS vs NEO, CDNA, PSNL: Cash Conversion Cycle Comparison
For the Diagnostics & Research subindustry, GeneDx Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneDx Holdings Cash Conversion Cycle vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GeneDx Holdings's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where GeneDx Holdings's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
GeneDx Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneDx Holdings (WGS) has a Cash Conversion Cycle of 81.33 as of Jun. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on GeneDx Holdings and its competitors.
Is GeneDx Holdings' Cash Conversion Cycle too high?
GeneDx Holdings' current Cash Conversion Cycle is 81.33. The Medical Diagnostics & Research industry median Cash Conversion Cycle is 70.16. GeneDx Holdings' value of 81.33 is 15.9% above this industry median. Overall, GeneDx Holdings has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' Cash Conversion Cycle compare to NEO and CDNA?
GeneDx Holdings' Cash Conversion Cycle of 81.33 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Cash Conversion Cycle is 70.16. GeneDx Holdings' value of 81.33 is 15.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Diagnostics & Research company?
The median Cash Conversion Cycle among Medical Diagnostics & Research companies is 70.16, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GeneDx Holdings's current Cash Conversion Cycle of 81.33 is 15.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on GeneDx Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Cash Conversion Cycle is 70.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneDx Holdings's current Cash Conversion Cycle is 81.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Modestly Overvalued. The stock's GF Value™ is $73.77, compared to a current price of $90.32 — trading 22.4% above its estimated fair value. The current Cash Conversion Cycle is 81.33 and 15.9% above the Medical Diagnostics & Research industry median of 70.16. GeneDx Holdings' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current Cash Conversion Cycle is 81.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneDx Holdings (WGS) Overvalued in 2026?
Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued.
The current stock price of $90.32 is trading 22.4% above its estimated GF Value™ of $73.77.
GuruFocus considers GeneDx Holdings to be Modestly Overvalued.
Key valuation signals for WGS:
Cash Conversion Cycle: 81.33
GF Value™: $73.77 vs. price of $90.32 (22.4% above fair value)
Industry Position: 15.9% above the Medical Diagnostics & Research median
No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
65GF Score
Get the complete analysis for WGS
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WGS has been successfully added to your 
